We have located links that may give you full text access.
Uric acid levels in patients on antituberculosis drugs in the Southwest region of Cameroon.
International Journal of Mycobacteriology 2016 December
OBJECTIVE/BACKGROUND: Antituberculosis drugs (ATDs) efficiently combat Mycobacterium tuberculosis either through direct molecular interactions or its metabolites. However, a variety of adverse effects have been reported, leading to frequent interruptions of treatment. In order to investigate possible metabolic disturbances resulting from antituberculosis treatment, the uric acid level of patients on ATDs was measured in the Southwest region of Cameroon.
METHODS: This hospital-based cross-sectional study involved 96 tuberculosis patients on ATDs and 32 controls who were neither on ATDs nor any other treatment that could increase uric acid levels. The hospital records of consenting participants were reviewed for medical history and questionnaires were issued. About 2-mL venous blood was collected and analyzed using spectrophotometer to determine uric acid levels.
RESULTS: Hyperuricemia was observed in 56/96 (58.3%) of the studied group as compared with four of 32 (12.5%) in the control group (p<0.001). Our results indicated that treatment duration was significantly associated with hyperuricemia (p=0.0016), while gender (p=0.1275) was not.
CONCLUSION: Hyperuricemia is associated with ATDs, with treatment duration being a significant factor. The disorder should be closely monitored, especially during the intensive phase of treatment.
METHODS: This hospital-based cross-sectional study involved 96 tuberculosis patients on ATDs and 32 controls who were neither on ATDs nor any other treatment that could increase uric acid levels. The hospital records of consenting participants were reviewed for medical history and questionnaires were issued. About 2-mL venous blood was collected and analyzed using spectrophotometer to determine uric acid levels.
RESULTS: Hyperuricemia was observed in 56/96 (58.3%) of the studied group as compared with four of 32 (12.5%) in the control group (p<0.001). Our results indicated that treatment duration was significantly associated with hyperuricemia (p=0.0016), while gender (p=0.1275) was not.
CONCLUSION: Hyperuricemia is associated with ATDs, with treatment duration being a significant factor. The disorder should be closely monitored, especially during the intensive phase of treatment.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app